Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results

C Gianniou, A Dirani, W Ferrini, L Marchionno,
D Decugis, A Deli, A Ambresin and I Mantel

Eye (2015) 29, 450–451; doi:10.1038/eye.2014.321

Correction to: *Eye* (2015) 29, 342–349;
doi:10.1038/eye.2014.258; published online
7 November 2014

Since the online publication of the above article,
the authors have noted that Figure 3 is incorrect.

Interval increased has been repeated and the
wording below the diagonal line should
be interval decreased. The corrected figure can
be found below.

The authors would like to apologise for this
error.

Figure 3 Distribution of the first measured interval after loading doses (horizontal axis), plotted against the last applied interval at month 24 (vertical axis), for all eyes that underwent treatment with ranibizumab for neovascular age-related macular degeneration according to the studied regimen 'observe and plan'. The term 'observation' is equivalent to any interval longer than 3 months. These eyes were followed regularly without planned injection.